Reinventing drug development from the ground up to make safe, effective oligonucleotide-based medicines possible on demand.
Creyon Bio has raised $40.0M in total funding. The most recent round was Series A. The last funding was announced in March 2022.
Creyon Bio's investors include Lux Capital, DCVC Bio, Alexandria Venture Investments, Casdin Capital, BioBrit.
Creyon Bio is headquartered in San Diego, United States.
Reinventing drug development from the ground up to make safe, effective oligonucleotide-based medicines possible on demand.
Creyon Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Creyon Bio — Funding & Investors." VCBacked, March 8, 2022, https://www.vcbacked.co/company/creyon-bio. Accessed August 6, 2026.
VCBacked. (2022). Creyon Bio — Funding & Investors. Retrieved August 6, 2026, from https://www.vcbacked.co/company/creyon-bio
{{cite web |title=Creyon Bio — Funding & Investors |url=https://www.vcbacked.co/company/creyon-bio |website=VCBacked |access-date=August 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated